IL280859A - Use of gboxdol for the treatment of gastrointestinal disorders and asthma - Google Patents

Use of gboxdol for the treatment of gastrointestinal disorders and asthma

Info

Publication number
IL280859A
IL280859A IL280859A IL28085921A IL280859A IL 280859 A IL280859 A IL 280859A IL 280859 A IL280859 A IL 280859A IL 28085921 A IL28085921 A IL 28085921A IL 280859 A IL280859 A IL 280859A
Authority
IL
Israel
Prior art keywords
gaboxadol
asthma
treatment
gastrointestinal tract
tract disorders
Prior art date
Application number
IL280859A
Other languages
English (en)
Hebrew (he)
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of IL280859A publication Critical patent/IL280859A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL280859A 2018-08-22 2021-02-14 Use of gboxdol for the treatment of gastrointestinal disorders and asthma IL280859A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862721013P 2018-08-22 2018-08-22
PCT/US2019/047673 WO2020041574A1 (en) 2018-08-22 2019-08-22 Use of gaboxadol in the treatment of gastrointestinal tract disorders and asthma

Publications (1)

Publication Number Publication Date
IL280859A true IL280859A (en) 2021-04-29

Family

ID=69591079

Family Applications (1)

Application Number Title Priority Date Filing Date
IL280859A IL280859A (en) 2018-08-22 2021-02-14 Use of gboxdol for the treatment of gastrointestinal disorders and asthma

Country Status (10)

Country Link
US (1) US20210177805A1 (enExample)
EP (1) EP3823619A4 (enExample)
JP (1) JP2021535106A (enExample)
KR (1) KR20210049855A (enExample)
CN (1) CN112888437A (enExample)
AU (1) AU2019326539A1 (enExample)
CA (1) CA3110218A1 (enExample)
IL (1) IL280859A (enExample)
MX (1) MX2021002113A (enExample)
WO (1) WO2020041574A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021174024A1 (en) 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
CN115551514A (zh) * 2020-03-25 2022-12-30 萨奇治疗股份有限公司 用于治疗呼吸系统病症的药物的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0974351A3 (en) * 1998-04-24 2000-12-13 Jouveinal Medicament for preventing and treating gastrointestinal damage
AU4307800A (en) * 1999-04-30 2000-11-17 Merab Lomia New indication for use of antiepileptic agents and medicines
EP1863808A1 (en) * 2005-03-18 2007-12-12 Transform Pharmaceuticals, Inc. Gaboxadol forms, compositions thereof, and related methods
US20070203216A1 (en) * 2006-02-14 2007-08-30 Bjarke Ebert Method of treating inflammatory diseases
CN108024997A (zh) * 2015-07-17 2018-05-11 奥维德医疗公司 用加波沙朵治疗发育障碍的方法

Also Published As

Publication number Publication date
CA3110218A1 (en) 2020-02-27
EP3823619A4 (en) 2021-11-17
WO2020041574A1 (en) 2020-02-27
EP3823619A1 (en) 2021-05-26
JP2021535106A (ja) 2021-12-16
US20210177805A1 (en) 2021-06-17
AU2019326539A1 (en) 2021-03-11
KR20210049855A (ko) 2021-05-06
MX2021002113A (es) 2021-06-23
CN112888437A (zh) 2021-06-01

Similar Documents

Publication Publication Date Title
IL281445A (en) Therapeutic nanoparticles and methods for their use
IL265315A (en) Methods and systems for adaptive treatment of gastrointestinal disorders
IL271117B (en) Diazabicyclic mutated imidazopyrimidines and their use in the treatment of respiratory disorders
IL275678A (en) Using nitrous oxide and inhaled oxygen to treat pulmonary hypertension
LT4014976T (lt) Aprocitentanas, skirtas panaudoti derinyje su valsartanu, gydant hipertenziją ir su ja susijusias ligas
IL271072A (en) Devices and methods for the treatment of body surface disorders
IL261932A (en) Use of probiotics in the treatment and/or prevention of eczema
IL272414A (en) Use of gaboksadol in the treatment of diabetes and related conditions
IL268210A (en) Use of gaboxadol in the treatment of tinnitus
IL273171A (en) Heterocyclic beta-hydroxyamines and their uses in the treatment of hyperglycemia
ZA201905402B (en) Compounds and their use in the treatment of schistosomiasis
IL260987A (en) Treatment and diagnosis of inflammatory disorders
IL284689A (en) Endoscopic device and methods of its use
IL277805A (en) Use of gaboksadol in the treatment of substance use disorders
IL267077A (en) New glutaminyl cyclase inhibitors and their use in the treatment of various diseases
PL3773615T3 (pl) Płynna kompozycja do stosowania w leczeniu błony śluzowej przewodu ustno-gardłowo-krtaniowo-przełykowego
EP3823619A4 (en) USE OF GABOXADOL FOR TREATMENT OF GIOMETAL TRACT DISORDERS AND ASTHMA
PL3541185T3 (pl) Zastosowanie 2-hydroksybenzyloaminy w leczeniu i zapobieganiu nadciśnieniu płucnemu
GB2574747B (en) Use of lambda interferons in the treatment of obesity-related disorders and related diseases
IL284032A (en) 3 beta-(benzyloxy)-17 alpha-methyl-paragan-5-en-20-one for use in the treatment of cognitive disorders
IL276792A (en) Inhaler and methods for using it
PL3937949T3 (pl) Fitoekdyzony i ich pochodne do ich zastosowania w leczeniu upośledzenia funkcji oddechowych
HK40053115A (en) Use of gaboxadol in the treatment of gastrointestinal tract disorders and asthma
AU2018903823A0 (en) Compositions and methods of treatment of conditions of the gastrointestinal tract
AU2019901175A0 (en) Compositions and methods of treatment of conditions of the gastrointestinal tract